Just because a business does not make any money, does not mean that the stock will go down. Indeed, Memphasys (ASX:MEM) stock is up 117% in the last year, providing strong gains for shareholders. But ...

Just because a business does not make any money, does not mean that the stock will go down. For example, Memphasys (ASX:MEM) shareholders have done very well over the last year, with the share price ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Memphasys Ltd ( (AU:MEM)) just unveiled ...

Memphasys Ltd is nearing the completion of its clinical trial for the Felix™ System, a groundbreaking sperm selection technology poised to revolutionize assisted reproductive treatments. With 95% of ...

Memphasys Ltd ( (AU:MEM)) has issued an announcement. Memphasys Limited has issued 26 million fully paid ordinary shares at a deemed issue price of $0.003 per share as consideration for corporate ...

An announcement from Memphasys Ltd ( (AU:MEM)) is now available. Memphasys Limited has raised $800,000 via a share placement at $0.005 per share, a discount to recent trading levels, with strong ...

Memphasys Limited has appointed Lindley Edwards as the new Non-Executive Chairperson, succeeding Robert Cooke, as the company nears the completion of its clinical trial for the Felix™ System. Edwards ...

Reproductive biotechnology company Memphasys looks to be hitting the mark in the high-value world of horse breeding after its Samson fertility diagnostic device achieved accuracy rates of more than 80 ...

Every investor in Memphasys Limited (ASX:MEM) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual to see ...

Memphasys has successfully collected data from approximately 240 horse inseminations to test its novel “SAMSON” stallion fertility diagnostic device that may cut sperm diagnosis times down to a rapid ...